p ampk (Cell Signaling Technology Inc)
Structured Review
P Ampk, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 96/100, based on 779 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/p+ampk/Phospho-AMPKalpha+(Thr172)+Rabbit+mAb/pm42887617-67-75-78
Average 96 stars, based on 779 article reviews
Images
Related Articles
other:Article Title: A promising magnesium-related alloy with metabolic reprogramming and antitumor effects in hepatocellular and pancreatic cancer Article Snippet: Equal amounts of protein were separated by SDS-PAGE and transferred onto PVDF membranes (Millipore, LG18-1501M − 1H). Article Title: Copper Depletion Nanoparticles Potentiate Cancer Immunotherapy by Avoiding Innate and Adaptive Immune Resistance. Article Snippet: The antibodies and reagents used in this research were as follows: β-Actin (#AF7018, Affinity), PD-L1 (#DF6526, Affinity; #ab205921, Abcam), CD47 (#DF6649, Affinity; #ab218810, Abcam), Blocking Assay:Article Title: Exploring the therapeutic mechanism of kaempferol in acute lung injury: Network pharmacology and experimental validation. Article Snippet: Acute lung injury (ALI) is a common and life-threatening respiratory disorder characterised by severe inflammation and persistently high mortality rates.. Kaempferol (KAE), a natural flavonoid compound, has diverse biological activities and holds potential for therapeutic applications.. In this study, we employed a network pharmacology approach to predict the mechanism through which KAE mitigates ALI; this mechanism was subsequently validated experimentally in a mouse model of ALI. Membrane:Article Title: Exploring the therapeutic mechanism of kaempferol in acute lung injury: Network pharmacology and experimental validation. Article Snippet: Acute lung injury (ALI) is a common and life-threatening respiratory disorder characterised by severe inflammation and persistently high mortality rates.. Kaempferol (KAE), a natural flavonoid compound, has diverse biological activities and holds potential for therapeutic applications.. In this study, we employed a network pharmacology approach to predict the mechanism through which KAE mitigates ALI; this mechanism was subsequently validated experimentally in a mouse model of ALI. Western Blot:Article Title: Low-dose juglone attenuates pressure overload-induced cardiac hypertrophy through Lys207-dependent FoxO1 activation and mitochondrial protection. Article Snippet: Cell Counting Kit-8 (CCK-8-100T, 96992) was purchased from Sigma-Aldrich. .. All primary antibodies against the indicated proteins used for immunoblotting, immunoprecipitation and immunostaining analysis in the present study are listed as follows: α-SMA (A2547, Sigma-Aldrich, USA), Collagen III (Abcam, ab184993), BNP (Abcam, ab19645), MYH7 (Cat: 22280-1, Protein tech), FoxO1 (#2880, CST), Pan-acetylation (Abcam, ab190479), Flag (F9291, SigmaAldrich, USA), α-actinin (Abcam, ab68194), CTnT (Abcam, ab209813), GAPDH (Abcam, ab8245), H3(Abcam, ab1791), β-actin (#8235, CST), Sesn3 (Abcam, ab97792), Pin1 (Abcam, 192036), 4-HNE (Thermo Fisher, MA5–27570), Sirt1 (Abcam, ab110304), Immunoprecipitation:Article Title: Low-dose juglone attenuates pressure overload-induced cardiac hypertrophy through Lys207-dependent FoxO1 activation and mitochondrial protection. Article Snippet: Cell Counting Kit-8 (CCK-8-100T, 96992) was purchased from Sigma-Aldrich. .. All primary antibodies against the indicated proteins used for immunoblotting, immunoprecipitation and immunostaining analysis in the present study are listed as follows: α-SMA (A2547, Sigma-Aldrich, USA), Collagen III (Abcam, ab184993), BNP (Abcam, ab19645), MYH7 (Cat: 22280-1, Protein tech), FoxO1 (#2880, CST), Pan-acetylation (Abcam, ab190479), Flag (F9291, SigmaAldrich, USA), α-actinin (Abcam, ab68194), CTnT (Abcam, ab209813), GAPDH (Abcam, ab8245), H3(Abcam, ab1791), β-actin (#8235, CST), Sesn3 (Abcam, ab97792), Pin1 (Abcam, 192036), 4-HNE (Thermo Fisher, MA5–27570), Sirt1 (Abcam, ab110304), Immunostaining:Article Title: Low-dose juglone attenuates pressure overload-induced cardiac hypertrophy through Lys207-dependent FoxO1 activation and mitochondrial protection. Article Snippet: Cell Counting Kit-8 (CCK-8-100T, 96992) was purchased from Sigma-Aldrich. .. All primary antibodies against the indicated proteins used for immunoblotting, immunoprecipitation and immunostaining analysis in the present study are listed as follows: α-SMA (A2547, Sigma-Aldrich, USA), Collagen III (Abcam, ab184993), BNP (Abcam, ab19645), MYH7 (Cat: 22280-1, Protein tech), FoxO1 (#2880, CST), Pan-acetylation (Abcam, ab190479), Flag (F9291, SigmaAldrich, USA), α-actinin (Abcam, ab68194), CTnT (Abcam, ab209813), GAPDH (Abcam, ab8245), H3(Abcam, ab1791), β-actin (#8235, CST), Sesn3 (Abcam, ab97792), Pin1 (Abcam, 192036), 4-HNE (Thermo Fisher, MA5–27570), Sirt1 (Abcam, ab110304), Analysis:Article Title: Low-dose juglone attenuates pressure overload-induced cardiac hypertrophy through Lys207-dependent FoxO1 activation and mitochondrial protection. Article Snippet: Cell Counting Kit-8 (CCK-8-100T, 96992) was purchased from Sigma-Aldrich. .. All primary antibodies against the indicated proteins used for immunoblotting, immunoprecipitation and immunostaining analysis in the present study are listed as follows: α-SMA (A2547, Sigma-Aldrich, USA), Collagen III (Abcam, ab184993), BNP (Abcam, ab19645), MYH7 (Cat: 22280-1, Protein tech), FoxO1 (#2880, CST), Pan-acetylation (Abcam, ab190479), Flag (F9291, SigmaAldrich, USA), α-actinin (Abcam, ab68194), CTnT (Abcam, ab209813), GAPDH (Abcam, ab8245), H3(Abcam, ab1791), β-actin (#8235, CST), Sesn3 (Abcam, ab97792), Pin1 (Abcam, 192036), 4-HNE (Thermo Fisher, MA5–27570), Sirt1 (Abcam, ab110304), Incubation:Article Title: Curcumin protects retinal photoreceptors in Glaucoma by activating prostaglandin D2 synthase-dependent NRF2 signaling. Article Snippet: This is a PDF of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability.. This version will undergo additional copyediting, typesetting and review before it is published in its final form.. As such, this version is no longer the Accepted Manuscript, but it is not yet the definitive Version of Record; we are providing this early version to give early visibility of the article. |

